Li Ou

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6101142/publications.pdf

Version: 2024-02-01

22	517	759233 12	677142 22
papers	citations	h-index	g-index

27	27	27	590
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Rare disease awareness and perspectives of physicians in China: a questionnaire-based study. Orphanet Journal of Rare Diseases, 2021, 16, 171.	2.7	28
2	Examination of a blood-brain barrier targeting Î²-galactosidase-monoclonal antibody fusion protein in a murine model of GM1-gangliosidosis. Molecular Genetics and Metabolism Reports, 2021, 27, 100748.	1.1	9
3	A questionnaire-based study to comprehensively assess the status quo of rare disease patients and care-givers in China. Orphanet Journal of Rare Diseases, 2021, 16, 327.	2.7	14
4	A novel gene editing system to treat both Tayâ€“Sachs and Sandhoff diseases. Gene Therapy, 2020, 27, 226-236.	4.5	39
5	The urgent need to empower rare disease organizations in China: an interview-based study. Orphanet Journal of Rare Diseases, 2020, 15, 282.	2.7	13
6	A Highly Efficacious PS Gene Editing System Corrects Metabolic and Neurological Complications of Mucopolysaccharidosis Type I. Molecular Therapy, 2020, 28, 1442-1454.	8.2	43
7	A longitudinal study of neurocognition and behavior in patients with Hurler-Scheie syndrome heterozygous for the L238Q mutation. Molecular Genetics and Metabolism Reports, 2019, 20, 100484.	1.1	3
8	Genotype-phenotype correlation of gangliosidosis mutations using in silico tools and homology modeling. Molecular Genetics and Metabolism Reports, 2019, 20, 100495.	1.1	11
9	ZFN-Mediated InÂVivo Genome Editing Corrects Murine Hurler Syndrome. Molecular Therapy, 2019, 27, 178-187.	8.2	63
10	Comprehensive behavioral and biochemical outcomes of novel murine models of GM1-gangliosidosis and Morquio syndrome type B. Molecular Genetics and Metabolism, 2019, 126, 139-150.	1.1	20
11	Metabolomics profiling reveals profound metabolic impairments in mice and patients with Sandhoff disease. Molecular Genetics and Metabolism, 2019, 126, 151-156.	1.1	15
12	SAAMP 2.0: An algorithm to predict genotypeâ€phenotype correlation of lysosomal storage diseases. Clinical Genetics, 2018, 93, 1008-1014.	2.0	9
13	Coping Strategies, Stress, and Support Needs in Caregivers of Children with Mucopolysaccharidosis. JIMD Reports, 2018, 42, 89-97.	1.5	12
14	Dose-Dependent Prevention of Metabolic and Neurologic Disease in Murine MPS II by ZFN-Mediated InÂVivo Genome Editing. Molecular Therapy, 2018, 26, 1127-1136.	8.2	103
15	RTB lectin-mediated delivery of lysosomal Î±-l -iduronidase mitigates disease manifestations systemically including the central nervous system. Molecular Genetics and Metabolism, 2018, 123, 105-111.	1.1	21
16	Proteomic analysis of mucopolysaccharidosis I mouse brain with two-dimensional polyacrylamide gel electrophoresis. Molecular Genetics and Metabolism, 2017, 120, 101-110.	1.1	12
17	Phenotype prediction for mucopolysaccharidosis type I by in silico analysis. Orphanet Journal of Rare Diseases, 2017, 12, 125.	2.7	25
18	485. ZFN-Mediated Liver-Targeting Gene Therapy Corrects Systemic and Neurological Disease of Mucopolysaccharidosis Type I. Molecular Therapy, 2016, 24, S192-S193.	8.2	1

#	Article	IF	Citations
19	484. In Vivo Zinc-Finger Nuclease Mediated Iduronate-2-Sulfatase (IDS) Target Gene Insertion and Correction of Metabolic Disease in a Mouse Model of Mucopolysaccharidosis Type II (MPS II). Molecular Therapy, 2016, 24, S192.	8.2	2
20	Elements of lentiviral vector design toward gene therapy for treating mucopolysaccharidosis I. Molecular Genetics and Metabolism Reports, 2016, 8, 87-93.	1.1	14
21	Standardization of Î±-L-iduronidase enzyme assay with Michaelisâ€“Menten kinetics. Molecular Genetics and Metabolism, 2014, 111, 113-115.	1.1	13
22	High-dose enzyme replacement therapy in murine Hurler syndrome. Molecular Genetics and Metabolism, 2014, 111, 116-122.	1.1	46